Saverio Caini1, Marco Del Riccio2, Virginia Vettori3, Vieri Scotti4, Chiara Martinoli5, Sara Raimondi5, Giulio Cammarata5, Domenico Palli6, Marco Banini7, Giovanna Masala8, Sara Gandini5. 1. Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. Electronic address: s.caini@ispro.toscana.it. 2. Postgraduate School in Hygiene and Preventive Medicine, University of Florence, Florence, Italy. 3. Department of Health Sciences, University of Florence, Florence, Italy. 4. Radiation Oncology Unit, Department of Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 5. Department of Experimental Oncology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. 6. Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. 7. Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio," University of Florence, Florence, Italy. 8. Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Abstract
INTRODUCTION: Lung cancer (LC) remains a disease with poor prognosis despite recent advances in treatments. Here, we aimed at summarizing the current scientific evidence on whether quitting smoking at or around diagnosis has a beneficial effect on the survival of LC patients. METHODS: We searched MEDLINE and EMBASE for articles published until 31st October, 2021, that quantified the impact on LC patients' survival of quitting smoking at or around diagnosis or during treatment. Study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models. RESULTS: Twenty-one articles published between 1980 and 2021 were included, which encompassed a total of over 10,000 LC patients. There was substantial variability across studies in terms of design, patients' characteristics, treatments received, criteria used to define smoking status (quitters or continued), and duration of follow-up. Quitting smoking at or around diagnosis was significantly associated with improved overall survival (SRR 0.71, 95% CI 0.64-0.80), consistently among patients with non-small cell LC (SRR 0.77, 95% CI 0.66-0.90, n studies = 8), small cell LC (SRR 0.75, 95% CI 0.57-0.99, n studies = 4), or LC of both or unspecified histological type (SRR 0.81, 95% CI 0.68-0.96, n studies = 6). CONCLUSIONS: Quitting smoking at or around diagnosis is associated with a beneficial effect on the survival of LC patients. Treating physicians should educate LC patients about the benefits of quitting smoking even after diagnosis and provide them with the necessary smoking cessation support.
INTRODUCTION: Lung cancer (LC) remains a disease with poor prognosis despite recent advances in treatments. Here, we aimed at summarizing the current scientific evidence on whether quitting smoking at or around diagnosis has a beneficial effect on the survival of LC patients. METHODS: We searched MEDLINE and EMBASE for articles published until 31st October, 2021, that quantified the impact on LC patients' survival of quitting smoking at or around diagnosis or during treatment. Study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models. RESULTS: Twenty-one articles published between 1980 and 2021 were included, which encompassed a total of over 10,000 LC patients. There was substantial variability across studies in terms of design, patients' characteristics, treatments received, criteria used to define smoking status (quitters or continued), and duration of follow-up. Quitting smoking at or around diagnosis was significantly associated with improved overall survival (SRR 0.71, 95% CI 0.64-0.80), consistently among patients with non-small cell LC (SRR 0.77, 95% CI 0.66-0.90, n studies = 8), small cell LC (SRR 0.75, 95% CI 0.57-0.99, n studies = 4), or LC of both or unspecified histological type (SRR 0.81, 95% CI 0.68-0.96, n studies = 6). CONCLUSIONS: Quitting smoking at or around diagnosis is associated with a beneficial effect on the survival of LC patients. Treating physicians should educate LC patients about the benefits of quitting smoking even after diagnosis and provide them with the necessary smoking cessation support.
Authors: Saverio Caini; Marco Del Riccio; Virginia Vettori; Oriana D'Ecclesiis; Pierluigi Bonomo; Luca Giovanni Locatello; Viola Salvestrini; Oreste Gallo; Marta Tagliabue; Sara Raimondi; Calogero Saieva; Flavia Cozzolino; Benedetta Bendinelli; Sara Gandini Journal: Br J Cancer Date: 2022-08-23 Impact factor: 9.075
Authors: Sarah Darmon; Amie Park; Leann A Lovejoy; Craig D Shriver; Kangmin Zhu; Rachel E Ellsworth Journal: Int J Environ Res Public Health Date: 2022-03-30 Impact factor: 3.390
Authors: Saverio Caini; Marco Del Riccio; Virginia Vettori; Sara Raimondi; Melania Assedi; Silvano Vignati; Guglielmo Bonaccorsi; Maria Sofia Cattaruzza; Federica Bellerba; Giulia Vagnoni; Giacomo Duroni; Sara Gandini Journal: Cancers (Basel) Date: 2022-08-09 Impact factor: 6.575
Authors: Shreya Chawla; Ishaan A Tewarie; Qingwei O Zhang; Alexander F C Hulsbergen; Rania A Mekary; Marike L D Broekman Journal: Neurosurg Rev Date: 2022-07-14 Impact factor: 2.800